New Alzheimer's Drug Candidate Shows Promise, Fast-Tracking to Clinical Trials

An experimental drug, KCL-286, originally developed for spinal cord injury, has demonstrated promising results in mouse studies by repairing DNA damage and reducing brain inflammation, suggesting it could quickly advance to Alzheimer's clinical testing after already clearing Phase 1 human safety trials.

The top 3

  1. First Ever FDA-Approved Alzheimer's Drug: Tacrine (Cognex) was the first drug approved by the FDA in 1993 for mild to moderate Alzheimer's disease, though its use has largely been discontinued due to liver toxicity and the introduction of newer drugs.
  2. Recent Amyloid-Targeting Drug Approvals: Lecanemab (Leqembi) and Donanemab (Kisunla) are two of the latest FDA-approved amyloid-beta targeting therapies, designed to clear plaques and slow cognitive decline in early Alzheimer's disease.
  3. Non-Amyloid Approaches Gaining Momentum: Beyond amyloid, research is increasingly focusing on other targets like tau protein pathology, neuroinflammation, and synaptic dysfunction, with several novel drug candidates in various stages of clinical trials.

Sources

Open the full topic